The Effectiveness of Continuous Ketamine Infusion (KONTINUE) (KONTINUE)
Effectiveness of Continuous Ketamine Infusion Associated with Magnesium Sulfate for Management of Patient with Chronic Pain : a Prospective Observational Study
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Ketamine continuous intravenous infusion for 4 days in Hospital with 0.5 mg/kg/day associated with Magnesium Sulfate 1000mg/day.
Evaluation schedules will be performed at day 15,30 and 60.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jean-Marie AMODEO, MD
- Phone Number: 00 377 97 98 97 02
- Email: jmamodeo@chpg.mc
Study Locations
-
-
-
Monaco, Monaco, 98000
- Centre Hospitalier Princesse Grace
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Pain lasting for more than six months without contraindication to treatment
Exclusion Criteria:
- Inability to give consent
- Severe psychiatric disorder
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Long-term effectiveness
Time Frame: 1 month
|
Improvement of the numerical scale - score 0 to 10 - 10 is the worst
|
1 month
|
|
Long-term effectiveness
Time Frame: 1 month
|
Clinical Global Impression of Change (CGI-C) - score 1 to 7 - 7 is the worst
|
1 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain relief
Time Frame: 15, 30, 60 days
|
Neuropathic Pain Symptom Inventory (NPSI) - score 0 to 10 - 10 is the worst
|
15, 30, 60 days
|
|
Variation of quality of life
Time Frame: 15, 30, 60 days
|
Short Form 12 health survey
|
15, 30, 60 days
|
|
Variation of quality of life
Time Frame: 15, 30, 60 days
|
Hospital Anxiety and Depression scale - score 0 to 21 - 21 is the worst
|
15, 30, 60 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 21-12
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.